Comparative Pharmacology
Head-to-head clinical analysis: LOSARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOSARTAN versus TEVETEN HCT.
Losartan vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Losartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing vasoconstriction, aldosterone secretion, and renal sodium reabsorption, leading to reduced blood pressure.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Losartan 50 mg orally once daily; may increase to 100 mg once daily based on blood pressure response.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Clinical Note
moderateLosartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid."
Clinical Note
moderateLosartan + Furosemide
"The risk or severity of adverse effects can be increased when Losartan is combined with Furosemide."
Clinical Note
moderateLosartan + Bumetanide
"The risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide."
Clinical Note
moderateLosartan + Benzydamine
Terminal half-life: 6-9 hours (losartan), 6-9 hours (active metabolite E-3174); clinical context: once-daily dosing is sufficient due to prolonged receptor binding
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Renal: 50% (parent drug and active metabolite), Biliary/Fecal: 50%
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination
"The risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine."